Safety evaluation of high‐dose intake of casein‐derived peptide Met‐Lys‐Pro in healthy adults: A randomized, double‐blind, placebo‐controlled trial

Met‐Lys‐Pro (MKP) is a casein‐derived angiotensin I‐converting enzyme inhibitory peptide with the potential to cross the blood–brain barrier. It has shown preventive effects against high blood pressure (BP) and cognitive decline in animal models and human studies. MKP shows good water solubility and can be blended into a variety of foods. However, its ease of intake may contribute to the possibility of overdose. Therefore, we aimed to evaluate the safety of high‐dose intake of MKP in healthy adults by conducting a randomized controlled trial with 30 subjects. Participants were randomly allocated to the MKP (n = 15) or placebo (n = 15) group. Over 4 weeks, the MKP group received test powder containing a daily dose of 1,000 μg of MKP, five times the minimum effective dose for cognitive improvement, whereas the placebo group received dextrin powder containing no detectable MKP. No clinical problems were observed in anthropometric and BP measurements or in blood and urine parameters. No adverse events owing to MKP intake were observed. These findings suggest that consumption of MKP is safe, and that it may be applicable as a safe preventive measure against hypertension and cognitive decline in future.